Soleno Therapeutics announces a $100 million share repurchase program to support confidence in its commercial launch of VYKAT XR.
Quiver AI Summary
Soleno Therapeutics, Inc. has announced a $100 million share repurchase plan authorized by its Board of Directors, which includes an Accelerated Share Repurchase Agreement with Jefferies LLC. This move reflects the company's confidence in the commercial launch of its drug, VYKAT XR, aimed at treating hyperphagia related to Prader-Willi syndrome. CEO Dr. Anish Bhatnagar emphasized the company achieved profitability in the third quarter of 2025 and believes the market underestimates its future financial potential, making share repurchase an attractive opportunity. The ASR will initially repurchase around 1.5 million shares based on the stock's closing price, with the total number to be finalized later, and is expected to conclude by the first quarter of 2026.
Potential Positives
- Authorization of a $100 million share repurchase demonstrates strong confidence from the Board in Soleno’s future performance and shareholder value.
- The company achieved profitability in the third quarter of 2025, highlighting financial health and operational success.
- Entering into an Accelerated Share Repurchase Agreement with Jefferies LLC underscores the company's positive outlook on its stock valuation and growth potential.
- The launch of VYKAT XR positions Soleno as a significant player in the rare disease market, particularly for Prader-Willi syndrome, indicating potential for sustained commercial success.
Potential Negatives
- Entering into a $100 million Accelerated Share Repurchase Agreement may raise concerns about the company's cash flow and financial priorities, particularly if future revenues do not materialize as expected.
- The reliance on forward-looking statements introduces uncertainty, as actual results could differ materially from expectations, potentially undermining investor confidence.
- While achieving profitability in the third quarter of 2025 is noted, there is no detailed information about the sustainability of this profitability, which could be a red flag for investors.
FAQ
What is the recent share repurchase authorized by Soleno Therapeutics?
Soleno Therapeutics has authorized a $100 million share repurchase program through an Accelerated Share Repurchase Agreement with Jefferies LLC.
What is the purpose of Soleno's share repurchase?
The repurchase demonstrates Soleno's confidence in its commercial launch and the potential for VYKAT XR as a foundational therapy for Prader-Willi syndrome.
When is the Accelerated Share Repurchase expected to be completed?
The ASR is anticipated to be completed in the first quarter of 2026.
How many shares will Soleno repurchase initially?
Soleno will make an initial delivery of approximately 1,511,553 shares based on the closing price from November 10, 2025.
What is VYKAT XR developed by Soleno Therapeutics?
VYKAT XR is a once-daily oral treatment for hyperphagia in individuals with Prader-Willi syndrome, including adults and children over 4 years old.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SLNO Insider Trading Activity
$SLNO insiders have traded $SLNO stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $SLNO stock by insiders over the last 6 months:
- PATRICIA C HIRANO (SEE REMARKS) has made 0 purchases and 2 sales selling 4,096 shares for an estimated $339,381.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SLNO Hedge Fund Activity
We have seen 147 institutional investors add shares of $SLNO stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 1,104,385 shares (+49.4%) to their portfolio in Q2 2025, for an estimated $92,525,375
- PERCEPTIVE ADVISORS LLC removed 1,076,163 shares (-71.4%) from their portfolio in Q2 2025, for an estimated $90,160,936
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,061,064 shares (+44.2%) to their portfolio in Q2 2025, for an estimated $88,895,941
- BLACKROCK, INC. added 931,421 shares (+48.7%) to their portfolio in Q2 2025, for an estimated $78,034,451
- POINT72 ASSET MANAGEMENT, L.P. removed 915,995 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $76,742,061
- CARLYLE GROUP INC. removed 860,980 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $58,202,247
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 816,732 shares (-18.6%) from their portfolio in Q2 2025, for an estimated $68,425,806
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SLNO Analyst Ratings
Wall Street analysts have issued reports on $SLNO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 08/27/2025
- Wells Fargo issued a "Overweight" rating on 08/20/2025
- Oppenheimer issued a "Outperform" rating on 08/07/2025
- Baird issued a "Outperform" rating on 07/11/2025
To track analyst ratings and price targets for $SLNO, check out Quiver Quantitative's $SLNO forecast page.
$SLNO Price Targets
Multiple analysts have issued price targets for $SLNO recently. We have seen 5 analysts offer price targets for $SLNO in the last 6 months, with a median target of $110.0.
Here are some recent targets:
- Derek Archila from Wells Fargo set a target price of $106.0 on 11/05/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $106.0 on 08/27/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 08/18/2025
- Leland Gershell from Oppenheimer set a target price of $110.0 on 08/07/2025
- Brian Skorney from Baird set a target price of $121.0 on 07/11/2025
Full Release
REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement (“ASR”) with Jefferies LLC (“Jefferies”) to repurchase $100 million of Soleno’s common stock.
“These actions demonstrate our confidence in our commercial launch and the compelling opportunity for VYKAT XR to become a foundational therapy for patients with hyperphagia associated with Prader Willi syndrome,” said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. “We achieved profitability in the third quarter of 2025 and we believe the expected future cash generation profile of our business is significantly underappreciated by the capital markets and that repurchasing shares of Soleno is a compelling and attractive opportunity.”
Under the ASR agreement, the company will make an initial payment of $100 million with an initial delivery of approximately 1,511,553 shares based on Soleno’s closing price on November 10, 2025. The final number of shares repurchased under the ASR will be based on the average of the volume-weighted price of Soleno’s common stock during the term of the transaction and will be subject to adjustments related to the terms and conditions of the ASR agreement. The ASR is expected to be completed in the first quarter of 2026.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT TM XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life .
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
